Journal Article

REGENERON PHARMACEUTICALS INC. and BAYER PHARMA AG v GENENTECH INC.

in Reports of Patent, Design and Trade Mark Cases

Volume 130, issue 9, pages 703-746
Published in print September 2013 | ISSN: 0080-1364
Published online September 2013 | e-ISSN: 1756-1000 | DOI: https://dx.doi.org/10.1093/rpc/rct055
REGENERON PHARMACEUTICALS INC. and BAYER PHARMA AG v GENENTECH INC.

Show Summary Details

Preview

H1 Patent: European patent: Treatment for age-related macular degeneration: Infringement: Validity: Construction: Whether claim required treatment of disease or identified undesirable characteristic: The specification as “dictionary” when construing claims: Novelty: Inventive step: Obviousness: Whether “obvious to try”: Whether fair expectation of success: Agrevo obviousness: Insufficiency: Extent of enablement required: Whether necessary to prove efficacy across full width of claim: Infringement/Insufficiency squeeze: Overlapping evidence given by two experts for same party: Whether necessary to cross-examine both experts: Practice: Appeal to Court of Appeal

Journal Article.  24167 words. 

Subjects: Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.